Blood biomarker eMTBR-tau may enable first-ever living diagnosis of CTE, JAMA studies show
EricTopol · x · 2026-11-20
CTE has only been diagnosable post-mortem, but two JAMA papers covered by the NYT may change that.
- Paper 1: A plasma eMTBR-tau immunoassay detected advanced insoluble tau pathology across 728 participants in 4 cohorts — levels were 50-fold higher at Braak stage VI vs stages I-II, and immunoassay correlated strongly with mass spectrometry (ρ 0.93-0.96).
- Paper 2: In 21 deceased former football players who underwent autopsy, plasma eMTBR-tau was significantly higher in CTE-positive donors, highest in high-stage CTE, and tracked tau burden across 11 brain regions.
Conclusion: eMTBR-tau is a promising candidate biomarker for in vivo CTE detection, pending larger validation studies for diagnostic accuracy and specificity.
More from Research
- Continual Learning's Real Bottleneck: The Unit Economics of the Improvement Loop — xennygrimmato_ · 2026-11-20
- LLM-free knowledge graph extraction with GLiNER: a hands-on writeup and the two fixes it needed — philipvollet · 2026-11-20
- Strategist evolves reasoning strategies as code, wins 24/30 benchmarks at 39% lower cost — liuzhuang1234 · 2026-11-20
- $1M into a public benchmark gets labs to spend $100M+ hillclimbing it — _jasonwei · 2026-11-20
- Practitioner: novelty search with agents is still extremely hard, but reveals a big capability overhang — generativist · 2026-11-20
- Stanford team at NeurIPS 2026: analogical reasoning fixes LLM mode collapse in science — james_y_zou · 2026-11-20